FHTX Foghorn Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1822462 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY357.3%
TTM net income YoY113.1%
TTM EPS YoY107.9%
Revenue 3-yr CAGR51.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin2.1%
Net margin8.4%
FCF margin-74.6%
EBITDA margin3.4%
Returns
ROE—
ROA4.8%
ROIC (approx.)—
Asset turnover0.57x
Leverage & solvency
Liabilities / assets107.4%
Debt / equity—
Current ratio4.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-8.88x
Accruals ratio47.0%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $83.54M | $16.07M | $3.27M | $9.25M | $8.15M | $7.56M | $5.95M | $2.86M |
| R&D expense | $18.84M | $18.52M | $18.26M | $22.05M | $20.00M | $21.79M | $21.63M | $20.51M |
| SG&A expense | $5.80M | $6.35M | $6.58M | $6.80M | $6.65M | $6.86M | $7.24M | $6.35M |
| Operating income | $56.64M | -$8.80M | -$21.57M | -$23.88M | -$18.50M | -$21.10M | -$22.91M | -$24.00M |
| Pretax income | — | — | — | — | — | — | — | -$19.50M |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | $58.15M | -$7.19M | -$19.88M | -$21.66M | -$15.85M | -$17.94M | -$18.83M | -$19.50M |
| EBITDA | $56.84M | -$8.61M | -$21.34M | -$23.08M | -$17.60M | -$20.20M | -$22.09M | -$23.24M |
| EPS (basic) | 0.81 | -0.10 | -0.29 | — | -0.25 | -0.28 | -0.30 | — |
| EPS (diluted) | 0.80 | -0.10 | -0.29 | — | -0.25 | -0.28 | -0.30 | — |
| Weighted avg. shares (diluted) | 72.59M | 70.63M | 69.54M | — | 63.03M | 62.98M | 62.85M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $80.30M | $68.08M | $87.66M | $80.88M | $89.33M | $72.57M | $61.03M | $57.16M |
| Current assets | $158.31M | $170.05M | $188.06M | $163.24M | $184.12M | $203.84M | $225.42M | $249.60M |
| PP&E, net | $1.29M | $1.50M | $1.71M | $1.92M | $8.66M | $9.51M | $10.35M | $9.96M |
| Total assets | $190.95M | $203.39M | $222.17M | $198.10M | $204.96M | $226.24M | $258.69M | $283.98M |
| Current liabilities | $37.31M | $50.58M | $64.40M | $59.74M | $85.09M | $77.79M | $71.31M | $66.99M |
| Total liabilities | $205.04M | $284.43M | $298.57M | $306.60M | $294.62M | $302.89M | $320.34M | $329.51M |
| Shareholders' equity | -$14.08M | -$81.04M | -$76.41M | -$108.50M | -$89.66M | -$76.66M | -$61.65M | -$45.53M |
| Shares outstanding | 59.96M | 58.71M | 58.71M | 56.66M | 56.54M | 55.80M | 55.72M | 55.59M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.24M | -$17.84M | -$25.27M | -$22.27M | -$18.86M | -$21.00M | -$23.97M | -$24.52M |
| Capital expenditure | $7,000 | $50,000 | $0 | $0 | $0 | $22,000 | $28,000 | $479,000 |
| Free cash flow | -$18.25M | -$17.89M | -$25.27M | -$22.27M | -$18.86M | -$21.02M | -$24.00M | -$25.00M |
| Investing cash flow | $24.19M | -$2.97M | -$17.72M | $13.23M | $35.57M | $33.83M | $29.40M | $22.29M |
| Financing cash flow | $6.28M | -$22,000 | $49.77M | $581,000 | $49,000 | $254,000 | $139,000 | $4,000 |
| Depreciation & amortization | $200,000 | $200,000 | $238,000 | $802,000 | $900,000 | $900,000 | $827,000 | $761,000 |
| Stock-based compensation | $2.52M | $2.55M | $2.38M | $2.24M | $2.73M | $2.73M | $2.69M | $2.48M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.